PT  - JOURNAL ARTICLE
AU  - Ding, Bo
AU  - Chen, Stephanie
AU  - Agrawal, Aayushi
AU  - Srivastava, Divyansh
AU  - Solorzano, Jaime
AU  - Cook, Bill
AU  - Papi, Alberto
AU  - Reddel, Helen K
TI  - Distribution of biomarkers in severe asthma and severe uncontrolled asthma
AID  - 10.1183/13993003.congress-2021.OA4214
DP  - 2021 Sep 05
TA  - European Respiratory Journal
PG  - OA4214
VI  - 58
IP  - suppl 65
4099  - http://erj.ersjournals.com/content/58/suppl_65/OA4214.short
4100  - http://erj.ersjournals.com/content/58/suppl_65/OA4214.full
SO  - Eur Respir J2021 Sep 05; 58
AB  - Introduction: Asthma is a heterogeneous condition and treatment response may vary. Understanding the distribution of biomarkers in patients with severe asthma despite treatment may help inform treatment decisions.Aim: To characterise the distribution of biomarkers in severe asthma.Methods: NOVELTY (NCT02760329) is a global, observational study of patients with physician-assigned asthma and/or COPD. This analysis included patients who at baseline had severe asthma or severe uncontrolled asthma and had biomarker and allergy history data. Asthma severity was physician-assessed, with uncontrolled asthma defined as an Asthma Control Test (ACT) score <20 or ≥1 exacerbation in the past 12 months. This analysis included history of allergy, high blood eosinophil (EOS) count (≥300 cells/µL) and high fractional exhaled nitric oxide (FeNO; ≥25 ppb).Results: Overall, 652 patients had physician-assessed severe asthma at baseline, and 480 (74%) of these met the criteria for severe uncontrolled asthma. Distribution of the 2 biomarkers and history of allergy were similar between these groups (figure). In both groups, 11.5% of patients were positive for all 3 variables (high EOS, high FeNO, history of allergy), and 13.3% of patients for none.Conclusion: The distribution and overlap of high EOS, high FeNO and history of allergy were similar among NOVELTY patients with severe asthma and the subset of these with severe uncontrolled asthma.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, OA4214.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).